417 related articles for article (PubMed ID: 28763628)
1. The value of 18F-FDG PET/CT imaging in breast cancer staging.
Yararbas U; Avci NC; Yeniay L; Argon AM
Bosn J Basic Med Sci; 2018 Feb; 18(1):72-79. PubMed ID: 28763628
[TBL] [Abstract][Full Text] [Related]
2. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
[TBL] [Abstract][Full Text] [Related]
3. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
[TBL] [Abstract][Full Text] [Related]
4. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
5. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.
Riedl CC; Slobod E; Jochelson M; Morrow M; Goldman DA; Gonen M; Weber WA; Ulaner GA
J Nucl Med; 2014 Oct; 55(10):1578-83. PubMed ID: 25214641
[TBL] [Abstract][Full Text] [Related]
7. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.
Groheux D; Giacchetti S; Espié M; Vercellino L; Hamy AS; Delord M; Berenger N; Toubert ME; Misset JL; Hindié E
J Nucl Med; 2011 Oct; 52(10):1526-34. PubMed ID: 21880576
[TBL] [Abstract][Full Text] [Related]
8. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
Fuster D; Duch J; Paredes P; Velasco M; Muñoz M; Santamaría G; Fontanillas M; Pons F
J Clin Oncol; 2008 Oct; 26(29):4746-51. PubMed ID: 18695254
[TBL] [Abstract][Full Text] [Related]
9. The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging.
Mittal BR; Manohar K; Kashyap R; Bhattacharya A; Singh B; Singh G
Hell J Nucl Med; 2011; 14(2):135-9. PubMed ID: 21761015
[TBL] [Abstract][Full Text] [Related]
10. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
[TBL] [Abstract][Full Text] [Related]
11. Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience.
Kim J; Lee J; Chang E; Kim S; Suh K; Sul J; Song I; Kim Y; Lee C
World J Surg; 2009 May; 33(5):943-9. PubMed ID: 19259728
[TBL] [Abstract][Full Text] [Related]
12. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
[TBL] [Abstract][Full Text] [Related]
13. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging.
Taira N; Ohsumi S; Takabatake D; Hara F; Takashima S; Aogi K; Takashima S; Inoue T; Sugata S; Nishimura R
Jpn J Clin Oncol; 2009 Jan; 39(1):16-21. PubMed ID: 18997183
[TBL] [Abstract][Full Text] [Related]
14. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Smith IC; Ogston KN; Whitford P; Smith FW; Sharp P; Norton M; Miller ID; Ah-See AK; Heys SD; Jibril JA; Eremin O
Ann Surg; 1998 Aug; 228(2):220-7. PubMed ID: 9712568
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET for axillary lymph node staging in primary breast cancer.
Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
[TBL] [Abstract][Full Text] [Related]
16. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.
Schirrmeister H; Kühn T; Guhlmann A; Santjohanser C; Hörster T; Nüssle K; Koretz K; Glatting G; Rieber A; Kreienberg R; Buck AC; Reske SN
Eur J Nucl Med; 2001 Mar; 28(3):351-8. PubMed ID: 11315604
[TBL] [Abstract][Full Text] [Related]
17. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.
Heusner TA; Kuemmel S; Hahn S; Koeninger A; Otterbach F; Hamami ME; Kimmig KR; Forsting M; Bockisch A; Antoch G; Stahl A
Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1543-50. PubMed ID: 19415270
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
20. Lack of clinical impact of
Liu J; Larcos G; Howle J; Veness M
Australas J Dermatol; 2017 May; 58(2):99-105. PubMed ID: 26459330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
